generic_name,reasoning,less_determination,binary_determination,less_determination_score,binary_determination_score,
MINOCYCLINE,"The drug label for ZILXI does not explicitly mention any pulmonary toxicity risks or pulmonary reactions associated with the drug itself. The provided text does not include any sentences that discuss pulmonary toxicity or pulmonary reactions directly related to ZILXI or its active ingredient, minocycline, when used topically. 
 

 However, it does mention that serious skin or allergic reactions have happened during treatment with minocycline taken by mouth that may affect parts of the body such as the liver, lungs, kidneys, and heart. This implies that oral minocycline has been associated with pulmonary reactions, but it does not state that ZILXI (topical minocycline) itself causes these reactions. 
 

 To summarize:
 - **Oral minocycline**: Associated with serious skin or allergic reactions that may affect the lungs.
 - **ZILXI (topical minocycline)**: No direct mention of pulmonary toxicity risks or pulmonary reactions.",Less,No,1,1,
LECANEMAB,"The drug label for LEQEMBI (lecanemab-irmb) does not explicitly mention any pulmonary toxicity risks or pulmonary reactions associated with the drug. The label primarily focuses on other types of adverse reactions and risks, such as Amyloid Related Imaging Abnormalities (ARIA), hypersensitivity reactions, and infusion-related reactions. 
 

 Here is a summary of the relevant sections that might indirectly relate to pulmonary issues, but none of these explicitly state that the drug itself causes pulmonary toxicity:
 

 1. **Infusion-Related Reactions**:
  - **Sentence**: ""Symptoms of infusion-related reactions include fever and flu-like symptoms (chills, generalized aches, feeling shaky, and joint pain), nausea, vomiting, hypotension, hypertension, and oxygen desaturation.""
  - **Summary**: This sentence mentions ""oxygen desaturation"" as a symptom of infusion-related reactions, which could be indirectly related to pulmonary function. However, it does not explicitly state that the drug itself causes pulmonary toxicity.
 

 2. **Hypersensitivity Reactions**:
  - **Sentence**: ""Hypersensitivity reactions, including angioedema, bronchospasm, and anaphylaxis, have occurred in patients who were treated with LEQEMBI.""
  - **Summary**: This sentence mentions ""bronchospasm"" as a type of hypersensitivity reaction, which is a pulmonary reaction. It states that this reaction has occurred in patients treated with LEQEMBI, but it does not explicitly state that the drug itself causes pulmonary toxicity.
 

 3. **Medication Guide**:
  - **Sentence**: ""Serious allergic reactions. Swelling of the face, lips, mouth, or tongue, hives, or difficulty breathing have happened during a LEQEMBI infusion.""
  - **Summary**: This sentence mentions ""difficulty breathing"" as a symptom of serious allergic reactions during a LEQEMBI infusion. It indicates that this reaction has happened during treatment but does not explicitly state that the drug itself causes pulmonary toxicity.
 

 In summary, while the drug label mentions some symptoms and reactions that could be related to pulmonary function (such as oxygen desaturation, bronchospasm, and difficulty breathing), it does not explicitly state that LEQEMBI itself causes pulmonary toxicity.",Less,No,1,3,
LINEZOLID,"The provided drug label for ZYVOX (linezolid) does not explicitly mention pulmonary toxicity risks or pulmonary reactions. The label primarily focuses on the indications, usage, dosage, administration, contraindications, warnings, precautions, adverse reactions, and other relevant information about the drug. 
 

 If you have any specific concerns or need information about potential pulmonary risks associated with ZYVOX, it is advisable to consult a healthcare professional or refer to more detailed medical literature.",No,No,1,1,
TAFLUPROST OPTHALMIC,"Here is a summary of all the sentences from the drug label that discuss pulmonary toxicity risks and pulmonary reactions for tafluprost ophthalmic solution:
 

 1. **""Respiratory disorders: exacerbation of asthma, dyspnea""**  
  - **Summary**: This sentence indicates that the drug has been associated with respiratory disorders, specifically exacerbation of asthma and dyspnea (difficulty breathing).
 

 2. **""worsening of asthma""**  
  - **Summary**: This sentence states that the drug has been associated with the worsening of asthma.
 

 3. **""shortness of breath""**  
  - **Summary**: This sentence indicates that the drug has been associated with causing shortness of breath.
 

 In summary, tafluprost ophthalmic solution has been associated with pulmonary risks, including exacerbation of asthma, dyspnea, and shortness of breath.",Most,Yes,1,1,
COBIMETINIB,"The drug label for COTELLIC (cobimetinib) includes the following information related to pulmonary toxicity risks and pulmonary reactions:
 

 1. **Section 6.1 Clinical Trials Experience (Unresectable or Metastatic Melanoma)**:
  - **Sentence**: ""The following clinically relevant adverse reactions (all grades) of COTELLIC were reported with <10% incidence in Trial 1: Respiratory, thoracic and mediastinal disorders: Pneumonitis.""
  - **Summary**: COTELLIC was associated with pneumonitis in less than 10% of patients in Trial 1.
 

 2. **Section 6.1 Clinical Trials Experience (Histiocytic Neoplasms)**:
  - **Sentence**: ""The following clinically relevant adverse reactions (all grades) of COTELLIC were reported with <15% incidence in Trial 2: Respiratory, thoracic, and mediastinal disorders: Hypoxia (12%), pulmonary edema (4%), and respiratory failure (8%).""
  - **Summary**: COTELLIC was associated with hypoxia (12%), pulmonary edema (4%), and respiratory failure (8%) in less than 15% of patients in Trial 2.
 

 3. **Table 5 Incidence of Adverse Reactions Reported Occurring in ≥15% (All Grades) or Any Percentage (Grade ≥3) in Patients with Histiocytic Neoplasms Treated with COTELLIC in Trial 2**:
  - **Sentence**: ""Pulmonary infections: Pneumonia and bronchitis (19% incidence).""
  - **Summary**: COTELLIC was associated with pulmonary infections, including pneumonia and bronchitis, in 19% of patients in Trial 2.
 

 4. **Table 5 Incidence of Adverse Reactions Reported Occurring in ≥15% (All Grades) or Any Percentage (Grade ≥3) in Patients with Histiocytic Neoplasms Treated with COTELLIC in Trial 2**:
  - **Sentence**: ""Dyspnea (27% incidence).""
  - **Summary**: COTELLIC was associated with dyspnea in 27% of patients in Trial 2.
 

 In summary, COTELLIC has been associated with various pulmonary risks and reactions, including pneumonitis, hypoxia, pulmonary edema, respiratory failure, pulmonary infections (pneumonia and bronchitis), and dyspnea, as observed in clinical trials.",Most,Yes,1,1,
TRAVOPROST OPHTHALMIC SOLUTION,"The provided drug label for Travoprost Ophthalmic Solution does not mention any pulmonary toxicity risks or pulmonary reactions. The label primarily focuses on the ophthalmic use of the drug, its indications, dosage, administration, contraindications, warnings, precautions, adverse reactions, and other relevant information. There are no sentences in the label that discuss pulmonary toxicity risks or pulmonary reactions associated with the use of this drug.",No,No,1,1,
DILTIAZEM HCI,"The provided drug label for Diltiazem Hydrochloride for Injection does not explicitly mention any pulmonary toxicity risks or pulmonary reactions associated with the drug itself. The label primarily focuses on the drug's pharmacology, indications, contraindications, warnings, precautions, drug interactions, adverse reactions, and dosage instructions. 
 

 Here is a summary of the relevant sections that might indirectly relate to pulmonary concerns, but none of these explicitly state that the drug itself causes pulmonary toxicity:
 

 1. **Hemodynamics**: The label mentions that in patients with cardiovascular disease, diltiazem hydrochloride injection administered intravenously reduced blood pressure, systemic vascular resistance, and coronary vascular resistance, and increased coronary blood flow. In patients with compromised myocardium, administration of intravenous diltiazem produced no significant effect on pulmonary capillary wedge pressure. This indicates that the drug does not significantly affect pulmonary pressure in these patients.
 

 2. **Warnings - Congestive Heart Failure**: The label states that experience with the use of diltiazem hydrochloride injection in patients with impaired ventricular function is limited and caution should be exercised when using the drug in such patients. This is a general caution and does not specifically mention pulmonary toxicity.
 

 3. **Adverse Reactions**: The label lists dyspnea (difficulty breathing) as an infrequent adverse reaction (less than 1%). However, it does not explicitly state that the drug causes pulmonary toxicity.
 

 4. **Overdosage**: The label provides measures for managing overdosage, including the administration of inotropic agents and diuretics for cardiac failure, but does not specifically mention pulmonary toxicity.
 

 In summary, the drug label does not provide any sentences that directly associate Diltiazem Hydrochloride for Injection with pulmonary toxicity risks or pulmonary reactions. The only mention of a pulmonary-related adverse reaction is dyspnea, which is listed as an infrequent occurrence.",No,No,2,1,
ALLOPURINOL,"The drug label for ALOPRIM (allopurinol) includes the following sentences that discuss pulmonary toxicity risks and pulmonary reactions:
 

 1. **""Pulmonary: respiratory failure/insufficiency, ARDS, increased respiration rate, apnea""**  
  - **Summary**: This sentence lists pulmonary reactions such as respiratory failure/insufficiency, Acute Respiratory Distress Syndrome (ARDS), increased respiration rate, and apnea.  
  - **Association/Causation**: The drug label does not explicitly state that ALOPRIM itself caused these pulmonary reactions, but these reactions were observed in patients treated with the drug.
 

 2. **""The safety of ALOPRIM was evaluated in an uncontrolled compassionate use study of 1,378 patients with advanced malignancies requiring treatment with cytotoxic chemotherapy and in patients with other serious conditions.""**  
  - **Summary**: This sentence provides context for the safety evaluation of ALOPRIM in a study involving patients with advanced malignancies and other serious conditions.  
  - **Association/Causation**: This sentence does not directly discuss pulmonary toxicity risks or reactions.
 

 3. **""Adverse reactions were reported in 9% (125/1378) of the patients treated with ALOPRIM.""**  
  - **Summary**: This sentence states that adverse reactions were reported in 9% of patients treated with ALOPRIM.  
  - **Association/Causation**: This sentence does not specify pulmonary reactions or causation.
 

 4. **""A listing of the adverse reactions reported from clinical trials follows: Incidence Less Than 1%: Pulmonary: respiratory failure/insufficiency, ARDS, increased respiration rate, apnea""**  
  - **Summary**: This sentence lists specific pulmonary adverse reactions observed in less than 1% of patients in clinical trials, including respiratory failure/insufficiency, ARDS, increased respiration rate, and apnea.  
  - **Association/Causation**: The drug label does not explicitly state that ALOPRIM itself caused these pulmonary reactions, but these reactions were observed in patients treated with the drug.
 

 In summary, the drug label mentions pulmonary reactions such as respiratory failure/insufficiency, ARDS, increased respiration rate, and apnea, which were observed in patients treated with ALOPRIM. However, it does not explicitly state that ALOPRIM itself caused these pulmonary reactions.",Less,Yes,1,1,
PEGUNIGALSIDASE ALFA,"The drug label for ELFABRIO (pegunigalsidase alfa-iwxj) does not explicitly mention pulmonary toxicity risks or pulmonary reactions. The label primarily focuses on hypersensitivity reactions, infusion-associated reactions, and other specific adverse effects such as membranoproliferative glomerulonephritis. 
 

 Here is a summary of the relevant sections that might indirectly relate to pulmonary issues, but none of these explicitly state that the drug itself is associated with or causes pulmonary toxicity:
 

 1. **Hypersensitivity Reactions Including Anaphylaxis**:
  - **Summary**: Hypersensitivity reactions, including anaphylaxis, have been reported. Symptoms included throat tightness, facial and oral edema, and moderate upper airway obstructions.
  - **Association**: The drug itself is associated with these hypersensitivity reactions.
 

 2. **Infusion-Associated Reactions (IARs)**:
  - **Summary**: IARs included symptoms such as dyspnea (difficulty breathing) and nasal congestion.
  - **Association**: The drug itself is associated with these infusion-associated reactions.
 

 3. **Warnings and Precautions**:
  - **Summary**: Patients with advanced Fabry disease may have compromised cardiac function, which may predispose them to a higher risk of severe complications from IARs.
  - **Association**: The drug itself is associated with a higher risk of severe complications in patients with compromised cardiac function, which could indirectly affect pulmonary function.
 

 In conclusion, while the drug label mentions symptoms that could involve pulmonary reactions (such as dyspnea and upper airway obstructions), it does not explicitly state that ELFABRIO causes pulmonary toxicity. The reactions are primarily related to hypersensitivity and infusion-associated responses.",Less,No,1,2,
CENOBAMATE,"The provided drug label for XCOPRI (cenobamate) does not explicitly mention pulmonary toxicity risks or pulmonary reactions. The label primarily focuses on other types of adverse reactions and warnings, such as hypersensitivity reactions, QT shortening, suicidal behavior and ideation, neurological adverse reactions, and the need for gradual withdrawal to avoid increased seizure frequency.
 

 Therefore, there are no sentences in the drug label that discuss pulmonary toxicity risks or pulmonary reactions associated with XCOPRI.",No,No,1,1,
METHYLPHENIDATE HYDROCHLORIDE,"The drug label for APTENSIO XR does not explicitly mention any pulmonary toxicity risks or pulmonary reactions associated with the drug itself. The detailed sections on warnings, precautions, adverse reactions, and clinical trials do not include any references to pulmonary toxicity or pulmonary reactions. Therefore, there are no sentences to summarize regarding pulmonary risks or reactions caused by APTENSIO XR.",No,No,1,1,
FEXOFENADINE HYDROCHLORIDE,"The provided drug label for fexofenadine hydrochloride does not explicitly mention any pulmonary toxicity risks or pulmonary reactions associated with the drug. The label primarily discusses the indications, dosage, contraindications, adverse reactions, drug interactions, use in specific populations, and other pharmacological details. 
 

 Here is a summary of the relevant sections that might indirectly relate to pulmonary concerns:
 

 1. **Adverse Reactions (Section 6)**:
  - The label lists various adverse reactions but does not specifically mention any pulmonary toxicity or reactions directly caused by fexofenadine hydrochloride.
 

 2. **Contraindications (Section 4)**:
  - The label states that fexofenadine hydrochloride is contraindicated in patients with known hypersensitivity to fexofenadine and any of its ingredients. Hypersensitivity reactions can include chest tightness and dyspnea (difficulty breathing), but these are not specifically labeled as pulmonary toxicity and are related to allergic reactions.
 

 3. **Postmarketing Experience (Section 6.2)**:
  - The label mentions that hypersensitivity reactions, including chest tightness and dyspnea, have been reported. These reactions are associated with hypersensitivity and not directly with pulmonary toxicity caused by the drug itself.
 

 In summary, the drug label does not provide any sentences that directly associate fexofenadine hydrochloride with pulmonary toxicity risks or pulmonary reactions. The only related mentions are hypersensitivity reactions that can include chest tightness and dyspnea, which are not classified as pulmonary toxicity.",No,No,1,1,
HUMAN BOTULINUM NEUROTOXIN A/B IMMUNE GLOBULIN,"Here is a summary of all the sentences from the drug label that discuss pulmonary toxicity risks and pulmonary reactions for BabyBIG:
 

 1. **Sentence:** ""IGIV recipients should be monitored for pulmonary adverse reactions, such as Transfusion-Related Acute Lung Injury (TRALI) (5.9).""
  - **Summary:** The drug label advises monitoring for pulmonary adverse reactions like TRALI in recipients of IGIV products, but it does not specifically state that BabyBIG itself is associated with or causes these reactions.
 

 2. **Sentence:** ""Non-cardiogenic pulmonary edema may occur in patients following IGIV treatment.""
  - **Summary:** The label mentions that non-cardiogenic pulmonary edema can occur following IGIV treatment, but it does not specifically attribute this risk to BabyBIG.
 

 3. **Sentence:** ""TRALI is characterized by severe respiratory distress, pulmonary edema, hypoxemia, normal left ventricular function, and fever.""
  - **Summary:** The label describes the characteristics of TRALI but does not state that BabyBIG causes this condition.
 

 4. **Sentence:** ""Monitor patients for pulmonary adverse reactions. If TRALI is suspected, perform appropriate tests for the presence of anti-neutrophil antibodies in both the product and patient serum.""
  - **Summary:** The label advises monitoring for pulmonary adverse reactions and testing for TRALI if suspected, without specifically attributing these reactions to BabyBIG.
 

 5. **Sentence:** ""TRALI may be managed using oxygen therapy with adequate ventilatory support.""
  - **Summary:** The label provides management guidelines for TRALI but does not state that BabyBIG causes this condition.
 

 In summary, the drug label discusses the need to monitor for pulmonary adverse reactions and describes TRALI, but it does not specifically state that BabyBIG itself is associated with or causes these pulmonary risks.",Less,No,1,2,The question is would you consider pulmonary edema a pulmonary toxicity or not. Technically it is a pulmonary toxicity. It doesn;t belong to the other classes of drug toxicities.
ALFUZOSIN HCL,"The drug label for UROXATRAL (alfuzosin HCl) does not explicitly mention any pulmonary toxicity risks or pulmonary reactions associated with the drug itself. The label provides comprehensive information on various aspects of the drug, including indications, dosage, contraindications, warnings, precautions, adverse reactions, and drug interactions, but it does not specifically address pulmonary toxicity or pulmonary reactions.
 

 Therefore, based on the provided drug label, there are no sentences that discuss pulmonary toxicity risks or pulmonary reactions for UROXATRAL.",No,No,1,1,
SIROLIMUS,"Here is a summary of all the sentences from the drug label that discuss pulmonary toxicity risks and pulmonary reactions for Rapamune (sirolimus):
 

 1. **Warning about Lung Transplantation – Bronchial Anastomotic Dehiscence:**
  - **Sentence:** ""Cases of bronchial anastomotic dehiscence, most fatal, have been reported in de novo lung transplant patients when Rapamune has been used as part of an immunosuppressive regimen.""
  - **Summary:** The drug itself was associated with fatal cases of bronchial anastomotic dehiscence in lung transplant patients.
 

 2. **Interstitial Lung Disease/Non-Infectious Pneumonitis:**
  - **Sentence:** ""Cases of interstitial lung disease [ILD] (including pneumonitis, bronchiolitis obliterans organizing pneumonia [BOOP], and pulmonary fibrosis), some fatal, with no identified infectious etiology have occurred in patients receiving immunosuppressive regimens including Rapamune.""
  - **Summary:** The drug itself was associated with cases of interstitial lung disease, including pneumonitis, BOOP, and pulmonary fibrosis, some of which were fatal.
 

 3. **Resolution of ILD upon Discontinuation or Dose Reduction:**
  - **Sentence:** ""In some cases, the ILD has resolved upon discontinuation or dose reduction of Rapamune.""
  - **Summary:** The drug itself was associated with ILD, which in some cases resolved when the drug was discontinued or the dose was reduced.
 

 4. **Risk Increase with Higher Trough Concentrations:**
  - **Sentence:** ""The risk may be increased as the trough sirolimus concentration increases.""
  - **Summary:** The drug itself was associated with an increased risk of ILD as the sirolimus concentration in the blood increases.
 

 5. **Postmarketing Experience – Respiratory:**
  - **Sentence:** ""Cases of interstitial lung disease (including pneumonitis, bronchiolitis obliterans organizing pneumonia [BOOP], and pulmonary fibrosis), some fatal, with no identified infectious etiology have occurred in patients receiving immunosuppressive regimens including Rapamune.""
  - **Summary:** The drug itself was associated with postmarketing cases of interstitial lung disease, including pneumonitis, BOOP, and pulmonary fibrosis, some of which were fatal.
 

 6. **Postmarketing Experience – Pulmonary Hemorrhage:**
  - **Sentence:** ""Pulmonary hemorrhage.""
  - **Summary:** The drug itself was associated with cases of pulmonary hemorrhage in postmarketing experience.
 

 7. **Postmarketing Experience – Pleural Effusion:**
  - **Sentence:** ""Pleural effusion.""
  - **Summary:** The drug itself was associated with cases of pleural effusion in postmarketing experience.
 

 8. **Postmarketing Experience – Alveolar Proteinosis:**
  - **Sentence:** ""Alveolar proteinosis.""
  - **Summary:** The drug itself was associated with cases of alveolar proteinosis in postmarketing experience.
 

 9. **Lung or Breathing Problems:**
  - **Sentence:** ""Lung or breathing problems. This can sometimes lead to death. Tell your doctor if you have a new or worsening cough, shortness of breath, difficulty breathing or any new breathing problems. Your doctor may need to stop Rapamune or lower your dose.""
  - **Summary:** The drug itself was associated with lung or breathing problems, which can sometimes be fatal, and may require discontinuation or dose reduction.
 

 These summaries indicate that Rapamune (sirolimus) is associated with several pulmonary risks and reactions, including fatal outcomes in some cases.",Most,Yes,1,1,
FOMEPIZOLE,"The drug label for Antizol (fomepizole) does not explicitly mention any pulmonary toxicity risks or pulmonary reactions directly associated with the drug itself. The label does discuss various adverse reactions and necessary precautions, but none are specifically related to pulmonary toxicity or reactions caused by the drug. Here is a summary of the relevant sections:
 

 1. **General Precautions**: The label mentions that patients intoxicated with ethylene glycol or methanol must be managed for adult respiratory distress syndrome, but this is related to the poisoning itself, not the administration of Antizol.
 

 2. **Laboratory Tests**: It is noted that patients should be monitored for various conditions, including adult respiratory distress syndrome, as part of the management of ethylene glycol or methanol poisoning. Again, this is related to the poisoning and not directly to the drug.
 

 3. **Adverse Reactions**: The label lists various adverse reactions, but none of them are pulmonary in nature or indicate that Antizol causes pulmonary toxicity.
 

 In summary, the drug label does not provide any information indicating that Antizol (fomepizole) itself is associated with or causes pulmonary toxicity or pulmonary reactions. The mention of respiratory distress is in the context of managing the symptoms of ethylene glycol or methanol poisoning, not as a direct effect of the drug.",No,No,1,1,
ROPINIROLE,"Here is a summary of all the sentences from the drug label that discuss pulmonary toxicity risks and pulmonary reactions for Ropinirole tablets:
 

 1. **Fibrotic Complications**:
  - **Sentence**: ""Cases of retroperitoneal fibrosis, pulmonary infiltrates, pleural effusion, pleural thickening, pericarditis, and cardiac valvulopathy have been reported in some patients treated with ergot-derived dopaminergic agents.""
  - **Summary**: This sentence does not associate Ropinirole itself with pulmonary risks but mentions that such complications have been reported with ergot-derived dopaminergic agents.
 

 2. **Fibrotic Complications**:
  - **Sentence**: ""Although these adverse reactions are believed to be related to the ergoline structure of these compounds, whether other, non-ergot-derived dopamine agonists such as ropinirole can cause them is unknown.""
  - **Summary**: This sentence states that it is unknown whether Ropinirole, a non-ergot-derived dopamine agonist, can cause these pulmonary risks.
 

 3. **Fibrotic Complications**:
  - **Sentence**: ""Cases of possible fibrotic complications, including pleural effusion, pleural fibrosis, interstitial lung disease, and cardiac valvulopathy have been reported in the development program and postmarketing experience for ropinirole.""
  - **Summary**: This sentence associates Ropinirole with possible fibrotic complications, including pulmonary risks such as pleural effusion, pleural fibrosis, and interstitial lung disease, based on development program and postmarketing reports.
 

 4. **Fibrotic Complications**:
  - **Sentence**: ""While the evidence is not sufficient to establish a causal relationship between ropinirole and these fibrotic complications, a contribution of ropinirole cannot be excluded.""
  - **Summary**: This sentence indicates that while there is insufficient evidence to establish a causal relationship between Ropinirole and these pulmonary risks, its contribution cannot be excluded.
 

 In summary, the drug label mentions that while it is unknown if Ropinirole can cause fibrotic complications, there have been reports of possible fibrotic complications, including pulmonary risks, in the development program and postmarketing experience. However, a causal relationship has not been definitively established.",Less,Yes,1,1,
ATRACURIUM BESYLATE,"Here is a summary of all the sentences from the drug label that discuss pulmonary toxicity risks and pulmonary reactions for Atracurium Besylate Injection USP:
 

 1. **""Rare instances of breathing difficulties, possibly related to incomplete reversal, have been reported following attempted pharmacologic antagonism of atracurium-induced neuromuscular block.""**
  - **Summary:** Breathing difficulties have been reported, possibly related to incomplete reversal of the drug's effects.
 

 2. **""Atracurium was discontinued in only one patient (who required treatment for bronchial secretions) and six other patients required treatment for adverse reactions attributable to atracurium (wheezing in one, hypotension in five).""**
  - **Summary:** One patient experienced bronchial secretions, and another experienced wheezing, both reactions attributable to the drug.
 

 3. **""Dyspnea, bronchospasm, laryngospasm""**
  - **Summary:** Dyspnea (difficulty breathing), bronchospasm, and laryngospasm have been reported, but it is not explicitly stated that these were caused by the drug.
 

 4. **""There have been rare spontaneous reports of seizures in ICU patients following long-term infusion of atracurium to support mechanical ventilation.""**
  - **Summary:** Seizures have been reported in ICU patients following long-term infusion of the drug, but it is not explicitly stated that the drug caused these seizures.
 

 5. **""There have been post-marketing reports of severe allergic reactions (anaphylactic and anaphylactoid reactions) associated with use of neuromuscular blocking agents, including atracurium besylate.""**
  - **Summary:** Severe allergic reactions, including anaphylactic and anaphylactoid reactions, have been associated with the use of the drug.
 

 In summary, the drug label indicates that atracurium besylate has been associated with various pulmonary reactions, including breathing difficulties, bronchial secretions, wheezing, dyspnea, bronchospasm, laryngospasm, and severe allergic reactions. However, it is not always explicitly stated that the drug caused these reactions.",Less,Yes,1,1,
"VENLAFAXINE HYDROCHLORIDE, EXTENDED RELEASE","Here is a summary of all the sentences from the drug label that discuss pulmonary toxicity risks and pulmonary reactions for Venlafaxine Hydrochloride Extended-Release Tablets:
 

 1. **Interstitial lung disease and eosinophilic pneumonia have been reported.**
  - **Summary:** The drug itself was associated with interstitial lung disease and eosinophilic pneumonia.
 

 2. **Interstitial lung disease and eosinophilic pneumonia associated with venlafaxine therapy have been rarely reported.**
  - **Summary:** The drug itself was associated with interstitial lung disease and eosinophilic pneumonia, although these cases are rare.
 

 3. **The possibility of these adverse reactions should be considered in venlafaxine-treated patients who present with progressive dyspnea, cough or chest discomfort.**
  - **Summary:** The drug itself was associated with the possibility of interstitial lung disease and eosinophilic pneumonia in patients presenting with progressive dyspnea, cough, or chest discomfort.
 

 4. **Such patients should undergo a prompt medical evaluation, and discontinuation of venlafaxine therapy should be considered.**
  - **Summary:** The drug itself was associated with the recommendation for prompt medical evaluation and potential discontinuation of therapy in patients presenting with symptoms suggestive of pulmonary toxicity.
 

 These sentences indicate that venlafaxine has been associated with rare cases of interstitial lung disease and eosinophilic pneumonia, and healthcare providers should be vigilant for these adverse reactions in patients undergoing treatment with this drug.",Less,Yes,1,1,
EVEROLIMUS,"Here is a summary of all the sentences from the drug label that discuss pulmonary toxicity risks and pulmonary reactions for AFINITOR/AFINITOR DISPERZ, clearly stating whether the drug itself was associated with or caused the pulmonary risk:
 

 1. **Non-infectious pneumonitis is a class effect of rapamycin derivatives.**
  - **Association:** The drug itself (AFINITOR/AFINITOR DISPERZ) is associated with this risk as it is a rapamycin derivative.
 

 2. **Non-infectious pneumonitis was reported in up to 19% of patients treated with AFINITOR/AFINITOR DISPERZ in clinical trials, some cases were reported with pulmonary hypertension (including pulmonary arterial hypertension) as a secondary event.**
  - **Association:** The drug itself caused non-infectious pneumonitis and was associated with secondary pulmonary hypertension.
 

 3. **The incidence of Grade 3 and 4 non-infectious pneumonitis was up to 4% and up to 0.2%, respectively.**
  - **Association:** The drug itself caused these severe grades of non-infectious pneumonitis.
 

 4. **Fatal outcomes have been observed.**
  - **Association:** The drug itself was associated with fatal outcomes due to non-infectious pneumonitis.
 

 5. **Consider a diagnosis of non-infectious pneumonitis in patients presenting with non-specific respiratory signs and symptoms.**
  - **Association:** The drug itself is associated with this risk, prompting the need for diagnosis consideration.
 

 6. **Continue AFINITOR/AFINITOR DISPERZ without dose alteration in patients who develop radiological changes suggestive of non-infectious pneumonitis and have few or no symptoms.**
  - **Association:** The drug itself is associated with radiological changes suggestive of non-infectious pneumonitis.
 

 7. **For Grade 2 to 4 non-infectious pneumonitis, withhold or permanently discontinue AFINITOR/AFINITOR DISPERZ based on severity.**
  - **Association:** The drug itself caused these severe grades of non-infectious pneumonitis.
 

 8. **The development of pneumonitis has been reported even at a reduced dose.**
  - **Association:** The drug itself caused pneumonitis even at reduced doses.
 

 9. **Infections, including pneumonia, have occurred.**
  - **Association:** The drug itself is associated with an increased risk of infections, including pneumonia.
 

 10. **The incidence of Grade 3 and 4 infections was up to 10% and up to 3%, respectively.**
  - **Association:** The drug itself caused these severe grades of infections, including pneumonia.
 

 11. **The incidence of serious infections was reported at a higher frequency in patients < 6 years of age.**
  - **Association:** The drug itself is associated with a higher frequency of serious infections, including pneumonia, in younger patients.
 

 12. **Administer prophylaxis for PJP when concomitant use of corticosteroids or other immunosuppressive agents are required.**
  - **Association:** The drug itself is associated with an increased risk of pneumocystis jiroveci pneumonia (PJP) when used with other immunosuppressive agents.
 

 13. **Radiation sensitization and recall, in some cases severe, involving cutaneous and visceral organs (including radiation esophagitis and pneumonitis) have been reported in patients treated with radiation prior to, during, or subsequent to AFINITOR/AFINITOR DISPERZ treatment.**
  - **Association:** The drug itself is associated with radiation sensitization and recall, including severe pneumonitis.
 

 14. **Monitor patients closely when AFINITOR/AFINITOR DISPERZ is administered during or sequentially with radiation treatment.**
  - **Association:** The drug itself is associated with an increased risk of radiation-induced pneumonitis.
 

 15. **Infections, stomatitis, and pneumonitis were the most common reasons for treatment delay or dose reduction.**
  - **Association:** The drug itself caused pneumonitis, leading to treatment delays or dose reductions.
 

 16. **Pneumonitis occurred in 14% of patients treated with AFINITOR in the RCC trial.**
  - **Association:** The drug itself caused pneumonitis in a significant percentage of patients in the RCC trial.
 

 17. **Pneumonitis was reported in 17% of patients treated with AFINITOR in the PNET trial.**
  - **Association:** The drug itself caused pneumonitis in a significant percentage of patients in the PNET trial.
 

 18. **Pneumonitis was reported in 19% of patients treated with AFINITOR in the breast cancer trial.**
  - **Association:** The drug itself caused pneumonitis in a significant percentage of patients in the breast cancer trial.
 

 19. **Pneumonitis was reported in 16% of patients treated with AFINITOR in the NET of GI or lung origin trial.**
  - **Association:** The drug itself caused pneumonitis in a significant percentage of patients in the NET of GI or lung origin trial.
 

 20. **Pneumonitis was reported in 1% of patients treated with AFINITOR in the TSC-associated renal angiomyolipoma trial.**
  - **Association:** The drug itself caused pneumonitis in a small percentage of patients in the TSC-associated renal angiomyolipoma trial.
 

 21. **Pneumonitis was reported in 1% of patients treated with AFINITOR in the TSC-associated SEGA trial.**
  - **Association:** The drug itself caused pneumonitis in a small percentage of patients in the TSC-associated SEGA trial.
 

 22. **Pneumonitis was reported in 0.8% of patients treated with AFINITOR DISPERZ in the TSC-associated partial-onset seizures trial.**
  - **Association:** The drug itself caused pneumonitis in a small percentage of patients in the TSC-associated partial-onset seizures trial.
 

 23. **Worsening side effects from radiation treatment, that can sometimes be severe.**
  - **Association:** The drug itself is associated with worsening side effects from radiation treatment, including severe pneumonitis.
 

 24. **Tell your healthcare provider if you have had or are planning to receive radiation therapy.**
  - **Association:** The drug itself is associated with an increased risk of radiation-induced pneumonitis.
 

 25. **Radiation sensitization and recall can occur in patients treated with radiation prior to, during, or subsequent to AFINITOR/AFINITOR DISPERZ treatment.**
  - **Association:** The drug itself is associated with radiation sensitization and recall, including pneumonitis.
 

 26. **Advise patients to inform their healthcare provider if they have had or are planning to receive radiation therapy.**
  - **Association:** The drug itself is associated with an increased risk of radiation-induced pneumonitis.",Most,Yes,1,1,
OXYCODONE HYDCHLORIDE,"Here is a summary of all the sentences from the drug label that discuss pulmonary toxicity risks and pulmonary reactions for oxycodone hydrochloride:
 

 1. **Respiratory Depression**: ""Respiratory depression is the chief hazard from all opioid agonist preparations."" 
  - **Summary**: The drug itself is associated with respiratory depression.
 

 2. **Respiratory Depression in Specific Populations**: ""Respiratory depression occurs most frequently in elderly or debilitated patients, usually following large initial doses in non-tolerant patients, or when opioids are given in conjunction with other agents that depress respiration.""
  - **Summary**: The drug itself is associated with respiratory depression, especially in elderly or debilitated patients and when combined with other respiratory depressants.
 

 3. **Caution in Patients with Respiratory Conditions**: ""Oxycodone hydrochloride tablets should be used with extreme caution in patients with significant chronic obstructive pulmonary disease or cor pulmonale, and in patients having substantially decreased respiratory reserve, hypoxia, hypercapnia, or pre-existing respiratory depression.""
  - **Summary**: The drug itself is associated with increased risk of respiratory depression in patients with pre-existing respiratory conditions.
 

 4. **Risk of Apnea**: ""In such patients, even usual therapeutic doses of oxycodone hydrochloride tablets may decrease respiratory drive to the point of apnea.""
  - **Summary**: The drug itself is associated with the risk of apnea in patients with pre-existing respiratory conditions.
 

 5. **Respiratory Depression in Head Injury**: ""The respiratory depressant effects of narcotics and their capacity to elevate cerebrospinal fluid pressure may be markedly exaggerated in the presence of head injury, other intracranial lesions or a pre-existing increase in intracranial pressure.""
  - **Summary**: The drug itself is associated with exaggerated respiratory depression in patients with head injuries or increased intracranial pressure.
 

 6. **Respiratory Depression in Overdose**: ""Acute overdose with oxycodone hydrochloride tablets can be manifested by respiratory depression, somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, constricted pupils, bradycardia, hypotension, and death.""
  - **Summary**: The drug itself is associated with respiratory depression in cases of overdose.
 

 7. **Respiratory Depression in Neonates**: ""Neonates whose mothers have taken oxycodone chronically may exhibit respiratory depression and/or withdrawal symptoms, either at birth and/or in the nursery.""
  - **Summary**: The drug itself is associated with respiratory depression in neonates born to mothers who have taken the drug chronically.
 

 8. **Respiratory Depression in Labor**: ""Neonates, whose mothers received opioid analgesics during labor, should be observed closely for signs of respiratory depression.""
  - **Summary**: The drug itself is associated with respiratory depression in neonates if the mother received the drug during labor.
 

 9. **Respiratory Depression in Nursing Infants**: ""Withdrawal symptoms can occur in breast-feeding infants when maternal administration of an opioid analgesic is stopped.""
  - **Summary**: The drug itself is associated with respiratory depression in nursing infants if the mother stops taking the drug abruptly.
 

 10. **Respiratory Depression in Adverse Reactions**: ""Serious adverse reactions that may be associated with oxycodone hydrochloride tablets therapy in clinical use are those observed with other opioid analgesics and include: respiratory depression, respiratory arrest, circulatory depression, cardiac arrest, hypotension, and/or shock.""
  - **Summary**: The drug itself is associated with respiratory depression as a serious adverse reaction.
 

 11. **Respiratory Depression in Drug Abuse and Dependence**: ""Infants born to mothers physically dependent on opioids will also be physically dependent and may exhibit respiratory difficulties and withdrawal symptoms.""
  - **Summary**: The drug itself is associated with respiratory difficulties in infants born to mothers who are physically dependent on the drug.
 

 In summary, oxycodone hydrochloride is associated with various pulmonary risks and reactions, including respiratory depression, apnea, and respiratory difficulties, particularly in specific populations such as the elderly, those with pre-existing respiratory conditions, neonates, and nursing infants.",Most,Yes,1,1,
LARONIDASE,"Here is a summary of all the sentences from the drug label that discuss pulmonary toxicity risks and pulmonary reactions for ALDURAZYME (laronidase):
 

 1. **""Patients with compromised respiratory function or acute respiratory disease may be at risk of serious acute exacerbation of their respiratory compromise due to infusion reactions and require additional monitoring.""**
  - **Summary:** The drug itself is associated with the risk of exacerbating respiratory compromise due to infusion reactions.
 

 2. **""Patients with compromised respiratory function or acute respiratory disease may be at risk of serious acute exacerbation of their respiratory compromise due to infusion reactions and require additional monitoring.""**
  - **Summary:** The drug itself is associated with the risk of exacerbating respiratory compromise due to infusion reactions.
 

 3. **""Patients with acute febrile or respiratory illness at the time of ALDURAZYME infusion may be at greater risk for infusion reactions.""**
  - **Summary:** The drug itself is associated with an increased risk of infusion reactions in patients with acute febrile or respiratory illness.
 

 4. **""Sleep apnea is common in MPS I patients. Consider evaluating airway patency prior to initiation of treatment with ALDURAZYME. Appropriate respiratory support should be available during infusion.""**
  - **Summary:** The drug itself is associated with the need for evaluating airway patency and having respiratory support available during infusion due to the commonality of sleep apnea in MPS I patients.
 

 5. **""Patients susceptible to fluid overload may be at increased risk for serious exacerbation of their cardiac or respiratory status during infusions.""**
  - **Summary:** The drug itself is associated with an increased risk of exacerbating respiratory status in patients susceptible to fluid overload during infusions.
 

 6. **""Hypersensitivity reactions including anaphylaxis have been reported in patients during or up to 3 hours after ALDURAZYME infusions. Some of these reactions were life-threatening and included respiratory failure, respiratory distress, stridor, tachypnea, bronchospasm, obstructive airways disorder, hypoxia, hypotension, bradycardia, and urticaria.""**
  - **Summary:** The drug itself is associated with hypersensitivity reactions that can lead to severe pulmonary reactions such as respiratory failure, respiratory distress, stridor, tachypnea, bronchospasm, obstructive airways disorder, and hypoxia.
 

 7. **""One patient with acute bronchitis and hypoxia experienced increased tachypnea during the first ALDURAZYME infusion that resolved without intervention. The patient's respiratory symptoms returned within 30 minutes of completing the infusion and responded to bronchodilator therapy. Approximately 6 hours after the infusion, the patient experienced coughing, then respiratory arrest, and died.""**
  - **Summary:** The drug itself was associated with increased tachypnea, respiratory symptoms, and ultimately respiratory arrest in a patient with acute bronchitis and hypoxia.
 

 8. **""Patients with an acute febrile or respiratory illness at the time of ALDURAZYME infusion may be at greater risk for infusion reactions.""**
  - **Summary:** The drug itself is associated with an increased risk of infusion reactions in patients with acute febrile or respiratory illness.
 

 9. **""Consider evaluating airway patency prior to initiation of treatment with ALDURAZYME. Patients using supplemental oxygen or continuous positive airway pressure (CPAP) during sleep should have these treatments readily available during infusion in the event of an infusion reaction, or extreme drowsiness/sleep induced by antihistamine use.""**
  - **Summary:** The drug itself is associated with the need for evaluating airway patency and having respiratory support available during infusion due to the risk of infusion reactions.
 

 10. **""In postmarketing experience, reports of acute cardiorespiratory failure have been reported with ALDURAZYME treatment.""**
  - **Summary:** The drug itself is associated with reports of acute cardiorespiratory failure in postmarketing experience.
 

 11. **""Patients susceptible to fluid overload, or patients with acute underlying respiratory illness or compromised cardiac and/or respiratory function for whom fluid restriction is indicated may be at increased risk of serious exacerbation of their cardiac or respiratory status during infusions.""**
  - **Summary:** The drug itself is associated with an increased risk of exacerbating respiratory status in patients susceptible to fluid overload or with underlying respiratory illness during infusions.
 

 12. **""In the MPS I Registry and other postmarketing setting, laronidase-specific IgE and/or IgG antibodies appeared to be associated with anaphylaxis and suspected hypersensitivity reactions in ALDURAZYME-treated patients.""**
  - **Summary:** The drug itself is associated with anaphylaxis and hypersensitivity reactions, which can include pulmonary reactions, in patients with laronidase-specific antibodies.
 

 13. **""In postmarketing experience with ALDURAZYME, severe and serious infusion reactions have been reported, some of which were life-threatening, including anaphylactic shock and laryngeal edema.""**
  - **Summary:** The drug itself is associated with severe and serious infusion reactions, including life-threatening pulmonary reactions such as anaphylactic shock and laryngeal edema.
 

 14. **""Adverse reactions resulting in death reported in the postmarketing setting with ALDURAZYME treatment included cardiorespiratory arrest, respiratory failure, cardiac failure, and pneumonia.""**
  - **Summary:** The drug itself is associated with adverse reactions resulting in death, including cardiorespiratory arrest, respiratory failure, and pneumonia.
 

 15. **""There have been a small number of reports of extravasation in patients treated with ALDURAZYME. There have been no reports of tissue necrosis associated with extravasation.""**
  - **Summary:** The drug itself is associated with extravasation, but no tissue necrosis has been reported.",Most,Yes,1,1,
"SILDENAFIL POWDER,","Here is a summary of all the sentences from the drug label that discuss pulmonary toxicity risks and pulmonary reactions for Sildenafil for Oral Suspension, along with a clear statement on whether the drug itself was associated with or caused the pulmonary risk:
 

 1. **Sentence:** ""Use in pulmonary veno-occlusive disease (PVOD) may cause pulmonary edema and is not recommended.""
  - **Summary:** Sildenafil use in patients with pulmonary veno-occlusive disease (PVOD) may cause pulmonary edema. The drug itself is associated with this pulmonary risk.
 

 2. **Sentence:** ""Pulmonary vasodilators may significantly worsen the cardiovascular status of patients with pulmonary veno-occlusive disease (PVOD).""
  - **Summary:** Pulmonary vasodilators, including Sildenafil, may worsen the cardiovascular status of patients with PVOD. The drug itself is associated with this pulmonary risk.
 

 3. **Sentence:** ""Should signs of pulmonary edema occur when sildenafil is administered, consider the possibility of associated PVOD.""
  - **Summary:** If pulmonary edema occurs during Sildenafil administration, PVOD should be considered as a possible cause. The drug itself is associated with this pulmonary risk.
 

 4. **Sentence:** ""Pulmonary hypertension (PH) secondary to sickle cell disease: Sildenafil for oral suspension may cause serious vaso-occlusive crises.""
  - **Summary:** Sildenafil may cause serious vaso-occlusive crises in patients with pulmonary hypertension secondary to sickle cell disease. The drug itself is associated with this pulmonary risk.
 

 5. **Sentence:** ""In a small, prematurely terminated study of patients with pulmonary hypertension (PH) secondary to sickle cell disease, vaso-occlusive crises requiring hospitalization were more commonly reported by patients who received sildenafil than by those randomized to placebo.""
  - **Summary:** In a study, patients with pulmonary hypertension secondary to sickle cell disease who received Sildenafil experienced more vaso-occlusive crises requiring hospitalization compared to those who received a placebo. The drug itself is associated with this pulmonary risk.
 

 6. **Sentence:** ""The effectiveness and safety of sildenafil in the treatment of PH secondary to sickle cell disease has not been established.""
  - **Summary:** The safety of Sildenafil in treating pulmonary hypertension secondary to sickle cell disease is not established, indicating potential risks. The drug itself is associated with this pulmonary risk.
 

 These sentences collectively indicate that Sildenafil for Oral Suspension is associated with specific pulmonary risks, particularly in patients with PVOD and pulmonary hypertension secondary to sickle cell disease.",Most,Yes,1,1,
IBALIZUMAB,"The drug label for TROGARZO (ibalizumab-uiyk) does not explicitly mention any pulmonary toxicity risks or pulmonary reactions. The label discusses various other risks and adverse reactions, such as hypersensitivity reactions, immune reconstitution inflammatory syndrome, and embryo-fetal toxicity, but it does not specifically address any pulmonary-related issues.
 

 Therefore, based on the provided drug label, there are no sentences that discuss pulmonary toxicity risks or pulmonary reactions associated with TROGARZO.",No,No,1,1,
BROMFENAC,"The provided drug label for BromSite (bromfenac ophthalmic solution) 0.075% does not contain any sentences that discuss pulmonary toxicity risks or pulmonary reactions. The label focuses on the ophthalmic use of the drug, its indications, dosage, administration, contraindications, warnings, precautions, adverse reactions, and other relevant information, but it does not mention any pulmonary-related risks or reactions. Therefore, there are no sentences to summarize regarding pulmonary toxicity or reactions associated with this drug.",No,No,1,1,
ALMOTRIPTAN,"The drug label for Almotriptan tablets does not explicitly mention pulmonary toxicity risks or pulmonary reactions. However, it does discuss cardiovascular and other systemic risks, which may indirectly affect pulmonary function. Here is a summary of the relevant sections:
 

 1. **Section 5.7 Increases in Blood Pressure**:
  - ""An 18% increase in mean pulmonary artery pressure was seen following dosing with another triptan in a study evaluating subjects undergoing cardiac catheterization.""
  - **Summary**: This sentence does not directly associate Almotriptan with increased pulmonary artery pressure but mentions that another triptan caused an increase in pulmonary artery pressure.
 

 2. **Section 10.1 Signs and Symptoms**:
  - ""Based on the pharmacology of triptans, hypertension or other more serious cardiovascular symptoms could occur after overdosage.""
  - **Summary**: This sentence suggests that hypertension, which could potentially affect pulmonary function, may occur with triptan overdosage. However, it does not specifically associate Almotriptan with pulmonary toxicity.
 

 3. **Section 5.1 Risk of Myocardial Ischemia and Infarction and Other Adverse Cardiac Events**:
  - ""Serious adverse cardiac events, including acute myocardial infarction, have been reported within a few hours following administration of almotriptan tablets.""
  - **Summary**: This sentence associates Almotriptan with serious cardiac events, which could indirectly impact pulmonary function, but does not specifically mention pulmonary toxicity.
 

 4. **Section 5.4 Other Vasospasm-Related Events, Including Peripheral Vascular Ischemia and Colonic Ischemia**:
  - ""Triptans, including almotriptan tablets, may cause vasospastic reactions other than coronary artery vasospasm, such as peripheral and gastrointestinal vascular ischemia with abdominal pain and bloody diarrhea.""
  - **Summary**: This sentence associates Almotriptan with vasospastic reactions, which could theoretically affect pulmonary vasculature, but does not specifically mention pulmonary toxicity.
 

 In summary, the drug label does not explicitly state that Almotriptan is associated with or causes pulmonary toxicity or specific pulmonary reactions. The closest mention is an increase in pulmonary artery pressure observed with another triptan, not Almotriptan.",No,No,1,1,
DEXAMETHASONE SODIUM PHOSPHATE,"The provided drug label for Dexamethasone Sodium Phosphate Injection, USP does not explicitly mention pulmonary toxicity risks or pulmonary reactions directly associated with the drug itself. The label primarily focuses on the drug's indications, usage, contraindications, warnings, precautions, adverse reactions, and dosage administration. 
 

 However, it does mention the use of the drug in treating certain respiratory diseases and conditions, which could imply its involvement in pulmonary contexts. Here are the relevant points:
 

 1. **Indications & Usage - Respiratory Diseases**:
  - The drug is indicated for the treatment of various respiratory diseases such as symptomatic sarcoidosis, berylliosis, fulminating or disseminated pulmonary tuberculosis (when used concurrently with appropriate anti-tuberculosis chemotherapy), Loeffler's syndrome not manageable by other means, and aspiration pneumonitis. 
  - **Summary**: The drug is used to treat certain pulmonary conditions, but the label does not state that the drug itself causes pulmonary toxicity.
 

 2. **Warnings - Serious Neurologic Adverse Reactions with Epidural Administration**:
  - The label warns about serious neurologic events, including stroke, which could indirectly affect pulmonary function due to compromised neurological control over respiratory muscles.
  - **Summary**: The drug, when administered epidurally, has been associated with serious neurologic events that could indirectly impact pulmonary function, but it does not directly cause pulmonary toxicity.
 

 3. **Precautions - Tuberculous Meningitis**:
  - The drug should be used with caution in patients with active tuberculosis, and close observation is necessary as reactivation of the disease may occur.
  - **Summary**: The drug may exacerbate pulmonary tuberculosis if not used cautiously, but it does not directly cause pulmonary toxicity.
 

 4. **Adverse Reactions - Respiratory**:
  - The label does not list specific pulmonary adverse reactions directly caused by the drug.
  - **Summary**: No direct pulmonary toxicity or reactions are listed as adverse effects of the drug.
 

 In conclusion, the drug label does not explicitly state that Dexamethasone Sodium Phosphate Injection, USP causes pulmonary toxicity or pulmonary reactions. Instead, it is used to treat certain pulmonary conditions and requires caution in patients with pulmonary tuberculosis.",No,No,1,1,
SELPERCATINIB,"Here is a summary of all the sentences from the drug label that discuss pulmonary toxicity risks and pulmonary reactions for RETEVMO (selpercatinib):
 

 1. **Interstitial Lung Disease (ILD)/Pneumonitis:**
  - **Sentence:** ""Severe, life-threatening, and fatal interstitial lung disease (ILD)/pneumonitis can occur in patients treated with RETEVMO.""
  - **Summary:** RETEVMO itself is associated with severe, life-threatening, and fatal ILD/pneumonitis.
 

 2. **Monitoring for Pulmonary Symptoms:**
  - **Sentence:** ""Monitor for pulmonary symptoms indicative of ILD/pneumonitis.""
  - **Summary:** Monitoring for pulmonary symptoms is recommended due to the risk associated with RETEVMO.
 

 3. **Withholding RETEVMO for Pulmonary Symptoms:**
  - **Sentence:** ""Withhold RETEVMO and promptly investigate for ILD in any patient who presents with acute or worsening of respiratory symptoms which may be indicative of ILD (e.g., dyspnea, cough, and fever).""
  - **Summary:** RETEVMO should be withheld and investigated if respiratory symptoms indicative of ILD occur, suggesting the drug is associated with these risks.
 

 4. **Dosage Adjustment Based on Severity:**
  - **Sentence:** ""Withhold, reduce dose or permanently discontinue RETEVMO based on severity of confirmed ILD.""
  - **Summary:** RETEVMO dosage should be adjusted or discontinued based on the severity of ILD, indicating the drug's association with this condition.
 

 5. **Clinical Trials Experience:**
  - **Sentence:** ""ILD/pneumonitis occurred in 1.8% of patients who received RETEVMO, including 0.3% with Grade 3 or 4 events, and 0.3% with fatal reactions.""
  - **Summary:** RETEVMO was associated with ILD/pneumonitis in 1.8% of patients, including severe and fatal cases.
 

 6. **Patient Counseling Information:**
  - **Sentence:** ""Advise patients that ILD/pneumonitis can occur and to contact their healthcare provider immediately for signs or symptoms of ILD including new or worsening cough or shortness of breath.""
  - **Summary:** Patients should be advised that ILD/pneumonitis can occur with RETEVMO and to seek medical attention for related symptoms, indicating the drug's association with these risks.
 

 7. **Patient Information Leaflet:**
  - **Sentence:** ""RETEVMO may cause severe or life-threatening inflammation of the lungs during treatment, that can lead to death.""
  - **Summary:** RETEVMO itself may cause severe or life-threatening lung inflammation, which can be fatal.
 

 8. **Symptoms to Report:**
  - **Sentence:** ""Tell your healthcare provider right away if you have any new or worsening lung symptoms, including shortness of breath, cough, fever.""
  - **Summary:** Patients are instructed to report new or worsening lung symptoms, indicating these symptoms are associated with RETEVMO.
 

 In summary, RETEVMO (selpercatinib) is associated with severe, life-threatening, and potentially fatal pulmonary toxicity risks, including interstitial lung disease (ILD) and pneumonitis. Monitoring, dosage adjustments, and patient counseling are recommended to manage these risks.",Most,Yes,1,1,
METHIMAZOLE,"The drug label for Methimazole discusses pulmonary toxicity risks and pulmonary reactions in the context of vasculitis. Here is a summary of the relevant sentences:
 

 1. **Sentence:** ""Cases of vasculitis resulting in severe complications have been reported in patients receiving methimazole therapy.""
  - **Summary:** Methimazole therapy has been associated with cases of vasculitis that resulted in severe complications.
 

 2. **Sentence:** ""These cases of vasculitis include: leukocytoclastic cutaneous vasculitis, acute kidney injury and glomerulonephritis, alveolar/pulmonary hemorrhage, CNS vasculitis, and neuropathy.""
  - **Summary:** Methimazole therapy has been associated with vasculitis cases that include alveolar/pulmonary hemorrhage among other complications.
 

 3. **Sentence:** ""Inform patients that cases of vasculitis resulting in severe complications have occurred with methimazole tablets.""
  - **Summary:** Methimazole tablets have been associated with cases of vasculitis that resulted in severe complications.
 

 4. **Sentence:** ""Inform patients to promptly report symptoms that may be associated with vasculitis including new rash, hematuria or decreased urine output, dyspnea or hemoptysis.""
  - **Summary:** Patients taking methimazole should be informed to report symptoms such as dyspnea or hemoptysis, which may be associated with vasculitis caused by the drug.
 

 In summary, Methimazole has been associated with pulmonary risks in the form of alveolar/pulmonary hemorrhage as part of vasculitis complications. Patients are advised to report pulmonary symptoms like dyspnea or hemoptysis, which may indicate vasculitis.",Most,Yes,1,1,
SUCCINYLCHOLINE CHLORIDE,"The drug label for Succinylcholine Chloride Injection does not explicitly mention pulmonary toxicity risks or pulmonary reactions directly associated with the drug. However, there are several points related to respiratory effects and risks that can be summarized:
 

 1. **Risk of Death Due to Medication Errors**: ""Administration of Succinylcholine Chloride Injection results in paralysis, which may lead to respiratory arrest and death; this progression may be more likely to occur in a patient for whom it is not intended."" 
  - **Summary**: The drug itself can cause respiratory arrest and death if administered incorrectly.
 

 2. **Prolonged Neuromuscular Block due to Phase II Block and Tachyphylaxis**: ""Prolonged respiratory muscle paralysis or weakness may be observed in patients manifesting this transition to Phase II block.""
  - **Summary**: The drug itself can cause prolonged respiratory muscle paralysis or weakness.
 

 3. **Prolonged Neuromuscular Block in Patients with Reduced Plasma Cholinesterase Activity**: ""If Succinylcholine Chloride Injection is administered to a patient homozygous for atypical plasma cholinesterase, resulting in apnea or prolonged muscle paralysis should be treated with controlled respiration.""
  - **Summary**: The drug itself can cause apnea or prolonged muscle paralysis in patients with reduced plasma cholinesterase activity.
 

 4. **Overdosage**: ""Overdosage with Succinylcholine Chloride Injection may result in neuromuscular block beyond the time needed for surgery and anesthesia. This may be manifested by skeletal muscle weakness, decreased respiratory reserve, low tidal volume, or apnea.""
  - **Summary**: The drug itself can cause decreased respiratory reserve, low tidal volume, or apnea in cases of overdosage.
 

 5. **Adverse Reactions**: ""Prolonged respiratory depression or apnea.""
  - **Summary**: The drug itself is associated with prolonged respiratory depression or apnea as an adverse reaction.
 

 6. **Mechanism of Action**: ""Succinylcholine has no effect on consciousness, pain threshold or cerebration.""
  - **Summary**: This statement clarifies that the drug does not affect consciousness, pain threshold, or cerebration, indirectly implying that respiratory effects are due to its neuromuscular blocking action.
 

 In summary, the drug label indicates that Succinylcholine Chloride Injection itself is associated with or can cause respiratory arrest, prolonged respiratory muscle paralysis, apnea, decreased respiratory reserve, low tidal volume, and prolonged respiratory depression.",Most,No,1,1,
RETIFANLIMAB-DLWR,"Here is a summary of all the sentences from the drug label that discuss pulmonary toxicity risks and pulmonary reactions for ZYNYZ (retifanlimab-dlwr):
 

 1. **""Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue, including the following: immune-mediated pneumonitis...""**
  - **Summary:** The drug itself is associated with immune-mediated pneumonitis, which can be severe or fatal.
 

 2. **""Immune-mediated pneumonitis occurred in 3% (13/440) of patients receiving ZYNYZ, including 1 (0.2%) patient with fatal pneumonitis, Grade 3 (0.9%), and Grade 2 (1.4%).""**
  - **Summary:** The drug itself caused immune-mediated pneumonitis in 3% of patients, including one fatal case.
 

 3. **""Pneumonitis led to permanent discontinuation of ZYNYZ in 1 patient and withholding of ZYNYZ in 0.9% of patients.""**
  - **Summary:** The drug itself caused pneumonitis severe enough to lead to permanent discontinuation in one patient and withholding in 0.9% of patients.
 

 4. **""Systemic corticosteroids were required in 77% (10/13) of patients with pneumonitis.""**
  - **Summary:** The drug itself caused pneumonitis that required systemic corticosteroids in 77% of affected patients.
 

 5. **""Pneumonitis resolved in 10 of the 13 patients.""**
  - **Summary:** The drug itself caused pneumonitis that resolved in 10 out of 13 patients.
 

 6. **""Of the 4 patients in whom ZYNYZ was withheld for pneumonitis, 3 reinitiated ZYNYZ after symptom improvement; of these, 1 had recurrence of pneumonitis.""**
  - **Summary:** The drug itself caused pneumonitis that led to withholding the drug in 4 patients, with 1 patient experiencing recurrence upon reinitiation.
 

 7. **""In patients treated with other PD-1/PD-L1–blocking antibodies, the incidence of pneumonitis is higher in patients who have received prior thoracic radiation.""**
  - **Summary:** The drug class (PD-1/PD-L1–blocking antibodies), which includes ZYNYZ, is associated with a higher incidence of pneumonitis in patients with prior thoracic radiation.
 

 8. **""A severe infusion-related reaction (Grade 3) occurred in 1 (0.2%) of 440 patients receiving ZYNYZ.""**
  - **Summary:** The drug itself caused a severe infusion-related reaction in 0.2% of patients, which could potentially include pulmonary symptoms.
 

 9. **""Advise patients to contact their healthcare provider immediately for signs or symptoms of pneumonitis, including new or worsening symptoms of cough, chest pain, or shortness of breath.""**
  - **Summary:** The drug itself is associated with the risk of pneumonitis, and patients are advised to seek medical attention for related symptoms.
 

 10. **""Lung problems: cough, shortness of breath, chest pain.""**
  - **Summary:** The drug itself is associated with lung problems, including cough, shortness of breath, and chest pain.
 

 These summaries indicate that ZYNYZ is associated with significant pulmonary toxicity risks, including immune-mediated pneumonitis, which can be severe or fatal.",Most,Yes,1,1,
ACETAZOLAMIDE EXTENDED-RELEASE,"Here is a summary of all the sentences from the drug label that discuss pulmonary toxicity risks and pulmonary reactions for Acetazolamide Extended Release:
 

 1. **""In patients with pulmonary obstruction or emphysema where alveolar ventilation may be impaired, acetazolamide which may precipitate or aggravate acidosis should be used with caution.""**
  - **Summary:** Acetazolamide itself may precipitate or aggravate acidosis in patients with pulmonary obstruction or emphysema.
 

 2. **""Gradual ascent is desirable to try to avoid acute mountain sickness. If rapid ascent is undertaken and acetazolamide is used, it should be noted that such use does not obviate the need for prompt descent if severe forms of high altitude sickness occur, i.e., high altitude pulmonary edema (HAPE) or high altitude cerebral edema.""**
  - **Summary:** Acetazolamide does not prevent the need for prompt descent in cases of severe high altitude sickness, including high altitude pulmonary edema (HAPE). The drug itself is not associated with causing HAPE but does not eliminate the risk.
 

 These sentences indicate that while acetazolamide may exacerbate acidosis in patients with certain pulmonary conditions, it does not directly cause high altitude pulmonary edema but does not prevent it either.",Less,No,1,1,
SACROSIDASE,"Here is a summary of all the sentences from the drug label that discuss pulmonary toxicity risks and pulmonary reactions for Sucraid (sacrosidase):
 

 1. **""Severe wheezing 90 minutes after a second dose of sacrosidase necessitated admission into the ICU for a 4-year-old boy.""**
  - **Summary:** Severe wheezing occurred 90 minutes after a second dose of sacrosidase, leading to ICU admission. 
  - **Association:** The drug itself was associated with the pulmonary reaction.
 

 2. **""The wheezing was probably caused by sacrosidase.""**
  - **Summary:** The wheezing was likely caused by sacrosidase.
  - **Association:** The drug itself was likely the cause of the pulmonary reaction.
 

 3. **""He had asthma and was being treated with steroids.""**
  - **Summary:** The patient had asthma and was on steroid treatment.
  - **Association:** This provides context about the patient's pre-existing condition but does not directly associate the drug with pulmonary toxicity.
 

 4. **""A skin test for sacrosidase was positive.""**
  - **Summary:** The patient had a positive skin test for sacrosidase.
  - **Association:** This indicates a hypersensitivity to the drug, which could be related to the pulmonary reaction.
 

 5. **""Other serious events have not been linked to Sucraid.""**
  - **Summary:** No other serious events have been linked to Sucraid.
  - **Association:** This clarifies that other serious pulmonary events have not been associated with the drug.
 

 6. **""One asthmatic child experienced a serious hypersensitivity reaction (wheezing) probably related to sacrosidase (see Warnings).""**
  - **Summary:** An asthmatic child experienced serious wheezing likely related to sacrosidase.
  - **Association:** The drug itself was likely the cause of the pulmonary reaction.
 

 In summary, the drug label indicates that sacrosidase was associated with severe wheezing in a child with asthma, and this reaction was likely caused by the drug. No other serious pulmonary events have been linked to Sucraid.",Less,Yes,1,1,
AVACOPAN,"The drug label for TAVNEOS (avacopan) does not explicitly mention pulmonary toxicity risks or pulmonary reactions associated with the drug itself. The label primarily focuses on other serious risks such as hepatotoxicity, hypersensitivity reactions, hepatitis B virus reactivation, and serious infections. The most common serious infections reported include pneumonia, but it does not specifically attribute this to pulmonary toxicity caused by TAVNEOS. Here is a summary of the relevant information:
 

 1. **Serious Infections**: The label mentions that serious infections, including fatal infections, have been reported in patients receiving TAVNEOS. The most common serious infections reported in the TAVNEOS group were pneumonia and urinary tract infections. However, it does not explicitly state that TAVNEOS itself caused these pulmonary infections (pneumonia).
 

 2. **Clinical Trials Experience**: In the phase 3 clinical trial, pneumonia was reported as a serious adverse reaction more frequently in patients treated with TAVNEOS (4.8%) compared to those treated with prednisone (3.7%). Again, the label does not explicitly state that TAVNEOS caused these pulmonary reactions.
 

 In summary, while pneumonia is mentioned as a serious infection observed in patients treated with TAVNEOS, the label does not explicitly attribute pulmonary toxicity or pulmonary reactions directly to the drug itself.",Less,No,1,1,
HYDRALAZINE HYDROCHLORIDE,"The drug label for Hydralazine Hydrochloride mentions the following points related to pulmonary toxicity risks and pulmonary reactions:
 

 1. **General Precautions Section:**
  - ""The 'hyperdynamic' circulation caused by hydrALAZINE may accentuate specific cardiovascular inadequacies. For example, hydrALAZINE may increase pulmonary artery pressure in patients with mitral valvular disease.""
  - **Summary:** Hydralazine itself may increase pulmonary artery pressure in patients with mitral valvular disease.
 

 2. **Adverse Reactions Section:**
  - ""Respiratory: dyspnea.""
  - **Summary:** Dyspnea (difficulty breathing) has been observed as an adverse reaction associated with Hydralazine.
 

 These are the sentences from the drug label that discuss pulmonary toxicity risks and pulmonary reactions, and they indicate that Hydralazine itself is associated with these risks.",Less,Yes,1,1,
DEFLAZACORT,"The drug label for EMFLAZA (deflazacort) does not explicitly mention pulmonary toxicity risks or pulmonary reactions. The label primarily focuses on other types of risks and adverse reactions, such as endocrine function alterations, immunosuppression, cardiovascular and renal function alterations, gastrointestinal perforation, behavioral and mood disturbances, effects on bones, ophthalmic effects, serious skin rashes, and various other conditions. 
 

 Therefore, there are no sentences in the provided drug label that discuss pulmonary toxicity risks or pulmonary reactions associated with EMFLAZA.",No,No,1,11,
BEVACIZUMAB,"Here is a summary of all the sentences from the drug label that discuss pulmonary toxicity risks and pulmonary reactions for Avastin (bevacizumab):
 

 1. **Serious or fatal pulmonary hemorrhage occurred in 31% of patients with squamous NSCLC and 4% of patients with non-squamous NSCLC receiving Avastin with chemotherapy compared to none of the patients receiving chemotherapy alone.**
  - **Summary:** Avastin was associated with serious or fatal pulmonary hemorrhage in patients with squamous and non-squamous NSCLC.
 

 2. **Do not administer Avastin to patients with recent history of hemoptysis of 1/2 teaspoon or more of red blood.**
  - **Summary:** Avastin is contraindicated in patients with a recent history of significant hemoptysis, indicating a risk of pulmonary hemorrhage associated with the drug.
 

 3. **Pulmonary embolism (5 vs. 1).**
  - **Summary:** Avastin was associated with a higher incidence of pulmonary embolism compared to the control group.
 

 4. **Serious or fatal pulmonary hemorrhage occurred in 31% of patients with squamous NSCLC and 4% of patients with non-squamous NSCLC receiving Avastin with chemotherapy compared to none of the patients receiving chemotherapy alone.**
  - **Summary:** Avastin was associated with a significant risk of serious or fatal pulmonary hemorrhage in patients with squamous and non-squamous NSCLC.
 

 5. **Fatal adverse reactions occurred in 4.6% of patients in the Avastin and atezolizumab arm. The most common adverse reactions leading to death were gastrointestinal and esophageal varices hemorrhage (1.2%) and infections (1.2%).**
  - **Summary:** While this sentence does not directly attribute pulmonary toxicity to Avastin, it mentions fatal adverse reactions, including hemorrhages, which could imply a risk of pulmonary hemorrhage.
 

 6. **Adverse reactions leading to discontinuation of Avastin occurred in 15% of patients in the Avastin and atezolizumab arm. The most common adverse reactions leading to Avastin discontinuation were hemorrhages (4.9%), including bleeding varicose vein, hemorrhage and gastrointestinal, subarachnoid, and pulmonary hemorrhages; and increased transaminases or bilirubin (0.9%).**
  - **Summary:** Avastin was associated with pulmonary hemorrhages leading to discontinuation of the drug.
 

 7. **Adverse reactions leading to interruption of Avastin occurred in 46% of patients in the Avastin and atezolizumab arm; the most common (≥ 2%) were proteinuria (6%); infections (6%); hypertension (6%); liver function laboratory abnormalities including increased transaminases, bilirubin, or alkaline phosphatase (4.6%); gastrointestinal hemorrhages (3%); thrombocytopenia/decreased platelet count (4.3%); and pyrexia (2.4%).**
  - **Summary:** This sentence does not directly attribute pulmonary toxicity to Avastin but mentions adverse reactions leading to interruption, including hemorrhages, which could imply a risk of pulmonary hemorrhage.
 

 8. **The following adverse reactions were reported at a 5-fold greater incidence in patients receiving Avastin with interferon-alfa compared to patients receiving placebo with interferon-alfa and not represented in Table 3: gingival bleeding (13 patients vs. 1 patient); rhinitis (9 vs. 0); blurred vision (8 vs. 0); gingivitis (8 vs. 1); gastroesophageal reflux disease (8 vs. 1); tinnitus (7 vs. 1); tooth abscess (7 vs. 0); mouth ulceration (6 vs. 0); acne (5 vs. 0); deafness (5 vs. 0); gastritis (5 vs. 0); gingival pain (5 vs. 0) and pulmonary embolism (5 vs. 1).**
  - **Summary:** Avastin was associated with a higher incidence of pulmonary embolism compared to the control group.
 

 9. **In an exploratory pooled analysis of 1745 patients from five randomized, controlled studies, 35% of patients were ≥ 65 years old. The overall incidence of ATE was increased in all patients receiving Avastin with chemotherapy as compared to those receiving chemotherapy alone, regardless of age; however, the increase in the incidence of ATE was greater in patients ≥ 65 years (8% vs. 3%) as compared to patients < 65 years (2% vs. 1%).**
  - **Summary:** This sentence does not directly attribute pulmonary toxicity to Avastin but mentions an increased incidence of arterial thromboembolic events (ATE), which could include pulmonary embolism.
 

 10. **In previously untreated patients with a hematological malignancy, the incidence of CHF and decline in left ventricular ejection fraction (LVEF) were increased in patients receiving Avastin with anthracycline-based chemotherapy compared to patients receiving placebo with the same chemotherapy regimen.**
  - **Summary:** This sentence does not directly attribute pulmonary toxicity to Avastin but mentions an increased incidence of congestive heart failure (CHF), which could have pulmonary implications.
 

 In summary, Avastin is associated with significant pulmonary risks, including pulmonary hemorrhage and pulmonary embolism, which have led to discontinuation or interruption of the drug in some patients.",Most,Yes,1,1,
VOSORITIDE,"The provided drug label for VOXZOGO (vosoritide) does not mention any pulmonary toxicity risks or pulmonary reactions. The label primarily discusses the drug's indications, dosage, administration, contraindications, warnings, precautions, adverse reactions, and other relevant information, but there is no specific mention of pulmonary toxicity or pulmonary reactions associated with the use of VOXZOGO.",No,No,1,1,
BEPOTASTINE BESILATE OPHTHALMIC SOLUTION 1.5%,"The provided drug label for Bepotastine Besilate Ophthalmic Solution 1.5% does not contain any sentences that discuss pulmonary toxicity risks or pulmonary reactions. Therefore, there is no information in the label indicating that the drug itself is associated with or causes pulmonary risks.",No,No,1,1,
PALONOSETRON,"The provided drug label for Palonosetron Hydrochloride Injection does not mention any specific pulmonary toxicity risks or pulmonary reactions associated with the drug. The label primarily focuses on the drug's indications, dosage, administration, contraindications, warnings, precautions, adverse reactions, and pharmacological details. 
 

 Here is a summary of the key points from the label, none of which specifically address pulmonary toxicity or reactions:
 

 1. **Indications and Usage**: The drug is indicated for the prevention of nausea and vomiting associated with chemotherapy and postoperative periods.
 2. **Dosage and Administration**: Detailed instructions on the recommended dosages for adults and pediatric patients.
 3. **Contraindications**: The drug is contraindicated in patients with known hypersensitivity to palonosetron.
 4. **Warnings and Precautions**: Includes warnings about hypersensitivity reactions and serotonin syndrome but does not mention pulmonary toxicity.
 5. **Adverse Reactions**: Lists common adverse reactions such as headache and constipation, and less common reactions, but does not include pulmonary reactions.
 6. **Drug Interactions**: Discusses interactions with serotonergic drugs but does not mention any pulmonary risks.
 7. **Use in Specific Populations**: Provides information on use during pregnancy, lactation, pediatric use, and geriatric use, without mentioning pulmonary risks.
 8. **Overdosage**: Describes the management of overdose but does not mention pulmonary toxicity.
 9. **Clinical Pharmacology**: Explains the mechanism of action, pharmacodynamics, and pharmacokinetics of the drug, with no mention of pulmonary toxicity.
 10. **Nonclinical Toxicology**: Discusses carcinogenesis, mutagenesis, and impairment of fertility, but not pulmonary toxicity.
 11. **Clinical Studies**: Summarizes the efficacy of the drug in preventing nausea and vomiting, with no mention of pulmonary reactions.
 12. **How Supplied/Storage and Handling**: Provides information on the drug's packaging and storage conditions.
 

 In conclusion, the drug label for Palonosetron Hydrochloride Injection does not discuss any pulmonary toxicity risks or pulmonary reactions associated with the drug.",No,No,1,1,
VIBEGRON,"The provided drug label for GEMTESA (vibegron) does not mention any pulmonary toxicity risks or pulmonary reactions. The label primarily discusses the drug's indications, dosage, administration, contraindications, warnings, precautions, adverse reactions, drug interactions, use in specific populations, and other relevant information. There is no specific mention of pulmonary toxicity or pulmonary reactions associated with GEMTESA in the provided text.",No,No,1,1,
PHENTERMINE HCL C-IV; PHENTERMINE HYDROCHLORIDE,"Here is a summary of all the sentences from the drug label that discuss pulmonary toxicity risks and pulmonary reactions for phentermine hydrochloride:
 

 1. **Primary Pulmonary Hypertension (PPH) - a rare, frequently fatal disease of the lungs - has been reported to occur in patients receiving a combination of phentermine with fenfluramine or dexfenfluramine.**
  - **Summary:** PPH has been reported in patients taking phentermine in combination with fenfluramine or dexfenfluramine. The drug itself was associated with the pulmonary risk when used in combination with these other drugs.
 

 2. **The possibility of an association between PPH and the use of phentermine alone cannot be ruled out; there have been rare cases of PPH in patients who reportedly have taken phentermine alone.**
  - **Summary:** There have been rare cases of PPH in patients taking phentermine alone, indicating a potential association between the drug itself and the pulmonary risk.
 

 3. **Patients should be advised to report immediately any deterioration in exercise tolerance.**
  - **Summary:** Patients are advised to report any deterioration in exercise tolerance, which is a precautionary measure related to potential pulmonary reactions. This does not directly state that the drug itself causes the pulmonary risk but implies monitoring for symptoms.
 

 4. **Treatment should be discontinued in patients who develop new, unexplained symptoms of dyspnea, angina pectoris, syncope or lower extremity edema, and patients should be evaluated for the possible presence of pulmonary hypertension.**
  - **Summary:** If patients develop new, unexplained symptoms such as dyspnea, they should discontinue the drug and be evaluated for pulmonary hypertension. This suggests that the drug itself may be associated with these pulmonary risks.
 

 5. **Primary pulmonary hypertension [see Warnings and Precautions (5.2)]**
  - **Summary:** This is a reference to the section discussing primary pulmonary hypertension, indicating that the drug label includes information about the potential pulmonary risk associated with the drug itself.
 

 In summary, the drug label indicates that phentermine, especially when used in combination with fenfluramine or dexfenfluramine, is associated with the risk of primary pulmonary hypertension. There are also rare cases of PPH reported with the use of phentermine alone, suggesting a potential association between the drug itself and pulmonary risks. Patients are advised to monitor for symptoms and discontinue use if unexplained pulmonary symptoms develop.",Most,Yes,1,1,
METHYLPHENIDATE HCL,"The provided drug label for Methylphenidate HCl Oral Solution does not contain any sentences that specifically discuss pulmonary toxicity risks or pulmonary reactions. The label primarily focuses on cardiovascular, psychiatric, and other systemic effects, but it does not mention any pulmonary-related risks or reactions associated with the drug. Therefore, there are no sentences to summarize regarding pulmonary toxicity or reactions for this medication.",No,No,1,1,
SUCRALFATE ORAL,"The drug label for Sucralfate Oral Suspension mentions pulmonary toxicity risks and pulmonary reactions in the following sentences:
 

 1. **""Fatal complications, including pulmonary and cerebral emboli have occurred with inappropriate intravenous administration of sucralfate oral suspension.""**
  - **Summary:** Pulmonary emboli have occurred due to inappropriate intravenous administration of the drug, not from the drug itself when used correctly.
 

 2. **""Post-marketing cases of hypersensitivity have been reported with the use of Sucralfate Oral Suspension, including anaphylactic reactions, dyspnea, lip swelling, edema of the mouth, pharyngeal edema, pruritus, rash, swelling of the face and urticaria.""**
  - **Summary:** Dyspnea (difficulty breathing) has been reported as a hypersensitivity reaction associated with the drug.
 

 3. **""Cases of bronchospasm, laryngeal edema and respiratory tract edema have been reported with an unknown oral formulation of sucralfate.""**
  - **Summary:** Bronchospasm, laryngeal edema, and respiratory tract edema have been reported, but it is unclear if these reactions are associated with this specific formulation of the drug.
 

 In summary, pulmonary emboli are linked to incorrect intravenous use of the drug, dyspnea is associated with hypersensitivity reactions to the drug, and bronchospasm, laryngeal edema, and respiratory tract edema have been reported but are not definitively linked to this specific formulation of sucralfate.",Less,No,1,1,
VARENICLINE; VARENICLINE TARTRATE,"The drug label for Varenicline Tablets does not explicitly mention pulmonary toxicity risks or pulmonary reactions directly associated with the drug itself. However, it does discuss the use of the drug in patients with chronic obstructive pulmonary disease (COPD). Here is a summary of the relevant information:
 

 1. **Subjects with Chronic Obstructive Pulmonary Disease (COPD)**
  - **Summary**: Varenicline tablets were evaluated in a randomized, double-blind, placebo-controlled study of subjects aged ≥ 35 years with mild-to-moderate COPD.
  - **Association with Pulmonary Risk**: The study was conducted on patients with pre-existing pulmonary conditions (COPD), but the label does not state that Varenicline itself caused or was associated with pulmonary toxicity or reactions.
 

 2. **Efficacy in COPD Patients**
  - **Summary**: Subjects treated with Varenicline tablets had a superior rate of CO-confirmed abstinence during weeks 9 through 12 (41%) compared to subjects treated with placebo (9%) and from week 9 through 52 (19%) compared to subjects treated with placebo (6%).
  - **Association with Pulmonary Risk**: This information highlights the efficacy of Varenicline in helping COPD patients quit smoking, but it does not indicate that the drug caused pulmonary toxicity or reactions.
 

 3. **Table 10: Continuous Abstinence (95% confidence interval), Studies in Patients with Chronic Obstructive Pulmonary Disease (COPD)**
  - **Summary**: The table provides data on the continuous abstinence rates for patients with COPD treated with Varenicline tablets versus placebo.
  - **Association with Pulmonary Risk**: The table presents efficacy data but does not discuss pulmonary toxicity or reactions caused by Varenicline.
 

 In conclusion, the drug label does not provide any sentences that directly associate Varenicline with causing pulmonary toxicity or reactions. The information provided is focused on the efficacy of the drug in helping patients with COPD quit smoking.",No,No,1,1,
NORTRIPTYLINE HCI,"The provided drug label for Nortriptyline Hydrochloride does not explicitly mention pulmonary toxicity risks or pulmonary reactions associated with the drug. The label extensively covers various other risks, side effects, and contraindications, but there is no specific mention of pulmonary toxicity or reactions directly linked to the use of Nortriptyline Hydrochloride.",No,No,1,1,
HYDROXYPROPYL CELLULOSE,"The drug label for LACRISERT (hydroxypropyl cellulose ophthalmic insert) does not mention any pulmonary toxicity risks or pulmonary reactions. Therefore, there are no sentences in the label that discuss pulmonary toxicity risks or pulmonary reactions associated with this drug.",No,No,1,1,
ETANERCEPT,"The drug label for Enbrel (etanercept) includes the following sentences that discuss pulmonary toxicity risks and pulmonary reactions:
 

 1. **""In clinical trials in rheumatologic indications, serious infections experienced by patients have included, but are not limited to, pneumonia, cellulitis, septic arthritis, bronchitis, gastroenteritis, pyelonephritis, sepsis, abscess and osteomyelitis.""**
  - **Summary:** Enbrel was associated with serious infections, including pneumonia and bronchitis.
 

 2. **""In clinical trials in adult PsO patients, serious infections experienced by patients have included, but are not limited to, pneumonia, cellulitis, gastroenteritis, abscess and osteomyelitis.""**
  - **Summary:** Enbrel was associated with serious infections, including pneumonia.
 

 3. **""Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis, and tuberculosis have been reported with TNF-blockers.""**
  - **Summary:** Enbrel, as a TNF-blocker, was associated with opportunistic infections, including pneumocystosis and tuberculosis.
 

 4. **""In 66 global clinical trials of 17,505 patients (21,015 patient-years of therapy), tuberculosis was observed in approximately 0.02% of patients.""**
  - **Summary:** Enbrel was associated with a low incidence of tuberculosis.
 

 5. **""In 17,696 patients (27,169 patient-years of therapy) from 38 clinical trials and 4 cohort studies in the U.S. and Canada, tuberculosis was observed in approximately 0.006% of patients.""**
  - **Summary:** Enbrel was associated with a very low incidence of tuberculosis.
 

 6. **""Tuberculosis should be strongly considered in patients who develop a new infection during Enbrel treatment, especially in patients who have previously or recently traveled to countries with a high prevalence of tuberculosis, or who have had close contact with a person with active tuberculosis.""**
  - **Summary:** Enbrel treatment is associated with a risk of tuberculosis, particularly in patients with relevant travel or contact history.
 

 7. **""Interstitial lung disease""**
  - **Summary:** Enbrel was associated with interstitial lung disease as a reported adverse reaction.
 

 In summary, Enbrel (etanercept) is associated with several pulmonary risks, including serious infections like pneumonia and bronchitis, opportunistic infections such as pneumocystosis and tuberculosis, and interstitial lung disease. These associations are based on clinical trial data and postmarketing reports.",Most,Yes,1,1,
NATEGLINIDE,The provided drug label for Nateglinide does not mention any pulmonary toxicity risks or pulmonary reactions. There are no sentences in the label that discuss pulmonary toxicity or pulmonary reactions associated with the drug.,No,No,1,1,
OXYCODONE HYDROCHLORIDE,"Here is a summary of all the sentences from the drug label that discuss pulmonary toxicity risks and pulmonary reactions for OXYCONTIN, along with a clear statement on whether the drug itself was associated with or caused the pulmonary risk:
 

 1. **Life-Threatening Respiratory Depression**:
  - **Sentence**: ""Serious, life-threatening, or fatal respiratory depression has been reported with the use of opioids, even when used as recommended.""
  - **Association**: The drug itself (OXYCONTIN) is associated with causing life-threatening respiratory depression.
 

 2. **Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly, Cachectic, or Debilitated Patients**:
  - **Sentence**: ""OXYCONTIN-treated patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with a substantially decreased respiratory reserve, hypoxia, hypercapnia, or pre-existing respiratory depression are at increased risk of decreased respiratory drive including apnea, even at recommended dosages of OXYCONTIN.""
  - **Association**: The drug itself (OXYCONTIN) is associated with causing decreased respiratory drive, including apnea, in patients with chronic pulmonary disease or other respiratory conditions.
 

 3. **Accidental Ingestion**:
  - **Sentence**: ""Accidental ingestion of even one dose of OXYCONTIN, especially by children, can result in respiratory depression and death due to an overdose of oxycodone.""
  - **Association**: The drug itself (OXYCONTIN) is associated with causing respiratory depression and death if accidentally ingested.
 

 4. **Patient Access to Naloxone for the Emergency Treatment of Opioid Overdose**:
  - **Sentence**: ""Discuss the availability of naloxone for the emergency treatment of opioid overdose with the patient and caregiver and assess the potential need for access to naloxone, both when initiating and renewing treatment with OXYCONTIN.""
  - **Association**: The drug itself (OXYCONTIN) is associated with the risk of opioid overdose, which can lead to respiratory depression.
 

 5. **Opioid-Induced Hyperalgesia and Allodynia**:
  - **Sentence**: ""Opioid-Induced Hyperalgesia (OIH) occurs when an opioid analgesic paradoxically causes an increase in pain, or an increase in sensitivity to pain.""
  - **Association**: This sentence does not directly discuss pulmonary risks but mentions a paradoxical reaction to opioids.
 

 6. **Adverse Reactions**:
  - **Sentence**: ""The most common adverse reactions (>5%) reported by patients in clinical trials comparing OXYCONTIN with placebo are shown in Table 2 below: Constipation (23%), Nausea (23%), Somnolence (23%), Dizziness (13%), Pruritus (13%), Vomiting (12%), Headache (7%), Dry Mouth (6%), Asthenia (6%), Sweating (5%).""
  - **Association**: This sentence lists common adverse reactions but does not directly discuss pulmonary risks.
 

 7. **Clinical Presentation of Overdose**:
  - **Sentence**: ""Acute overdose with oxycodone can be manifested by respiratory depression, somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, constricted pupils, and in some cases, pulmonary edema, bradycardia, hypotension, hypoglycemia, partial or complete airway obstruction, atypical snoring, and death.""
  - **Association**: The drug itself (OXYCONTIN) is associated with causing respiratory depression and pulmonary edema in cases of overdose.
 

 8. **Treatment of Overdose**:
  - **Sentence**: ""Opioid antagonists, such as naloxone, are specific antidotes to respiratory depression resulting from opioid overdose.""
  - **Association**: The drug itself (OXYCONTIN) is associated with causing respiratory depression in overdose situations.
 

 9. **Effects on the Central Nervous System**:
  - **Sentence**: ""Oxycodone produces respiratory depression by direct action on brain stem respiratory centers.""
  - **Association**: The drug itself (OXYCONTIN) is associated with causing respiratory depression through its action on the brain stem.
 

 10. **Effects on the Cardiovascular System**:
  - **Sentence**: ""Oxycodone produces peripheral vasodilation which may result in orthostatic hypotension or syncope.""
  - **Association**: This sentence discusses cardiovascular effects but does not directly discuss pulmonary risks.
 

 11. **Effects on the Endocrine System**:
  - **Sentence**: ""Opioids inhibit the secretion of adrenocorticotropic hormone (ACTH), cortisol, and luteinizing hormone (LH) in humans.""
  - **Association**: This sentence discusses endocrine effects but does not directly discuss pulmonary risks.
 

 12. **Effects on the Immune System**:
  - **Sentence**: ""Opioids have been shown to have a variety of effects on components of the immune system in in vitro and animal models.""
  - **Association**: This sentence discusses immune system effects but does not directly discuss pulmonary risks.
 

 13. **Concentration –Efficacy Relationships**:
  - **Sentence**: ""Studies in normal volunteers and patients reveal predictable relationships between oxycodone dosage and plasma oxycodone concentrations, as well as between concentration and certain expected opioid effects, such as pupillary constriction, sedation, overall subjective 'drug effect', analgesia and feelings of relaxation.""
  - **Association**: This sentence discusses the relationship between dosage and effects but does not directly discuss pulmonary risks.
 

 14. **Concentration –Adverse Reaction Relationships**:
  - **Sentence**: ""There is a relationship between increasing oxycodone plasma concentration and increasing frequency of dose-related opioid adverse reactions such as nausea, vomiting, CNS effects, and respiratory depression.""
  - **Association**: The drug itself (OXYCONTIN) is associated with causing respiratory depression as plasma concentration increases.
 

 15. **Specific Populations - Age: Geriatric Population**:
  - **Sentence**: ""Respiratory depression is the chief risk for elderly patients treated with opioids and has occurred after large initial doses were administered to patients who are not opioid-tolerant or when opioids were co-administered with other agents that depress respiration.""
  - **Association**: The drug itself (OXYCONTIN) is associated with causing respiratory depression in elderly patients.
 

 16. **Specific Populations - Hepatic Impairment**:
  - **Sentence**: ""Regularly evaluate closely for signs of respiratory depression, sedation, and hypotension.""
  - **Association**: The drug itself (OXYCONTIN) is associated with causing respiratory depression in patients with hepatic impairment.
 

 17. **Specific Populations - Renal Impairment**:
  - **Sentence**: ""Follow a conservative approach to dose initiation and adjust according to the clinical situation.""
  - **Association**: This sentence advises caution but does not directly discuss pulmonary risks.
 

 18. **Specific Populations - Sex Differences**:
  - **Sentence**: ""The clinical relevance of a difference of this magnitude is low for a drug intended for chronic usage at individualized dosages, and there was no male/female difference detected for efficacy or adverse events in clinical trials.""
  - **Association**: This sentence discusses sex differences but does not directly discuss pulmonary risks.
 

 19. **Drug Interaction Studies - CYP3A4 Inhibitors**:
  - **Sentence**: ""Co-administration of OXYCONTIN (10 mg single dose) and the CYP3A4 inhibitor ketoconazole (200 mg BID) increased oxycodone AUC and Cmax by 170% and 100%, respectively.""
  - **Association**: This sentence discusses drug interactions but does not directly discuss pulmonary risks.
 

 20. **Drug Interaction Studies - CYP3A4 Inducers**:
  - **Sentence**: ""A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.""
  - **Association**: This sentence discusses drug interactions but does not directly discuss pulmonary risks.
 

 21. **Drug Interaction Studies - CYP2D6 Inhibitors**:
  - **Sentence**: ""Oxycodone is metabolized in part to oxymorphone via CYP2D6.""
  - **Association**: This sentence discusses drug interactions but does not directly discuss pulmonary risks.
 

 22. **Nonclinical Toxicology - Carcinogenesis**:
  - **Sentence**: ""Carcinogenic potential of oxycodone was evaluated in a 2-year oral gavage study in Sprague-Dawley rats.""
  - **Association**: This sentence discusses carcinogenesis but does not directly discuss pulmonary risks.
 

 23. **Nonclinical Toxicology - Mutagenesis**:
  - **Sentence**: ""Oxycodone was genotoxic in the in vitro mouse lymphoma assay.""
  - **Association**: This sentence discusses mutagenesis but does not directly discuss pulmonary risks.
 

 24. **Nonclinical Toxicology - Impairment of Fertility**:
  - **Sentence**: ""In a study of reproductive performance, rats were administered a once daily gavage dose of the vehicle or oxycodone hydrochloride.""
  - **Association**: This sentence discusses fertility but does not directly discuss pulmonary risks.
 

 25. **Clinical Studies - Adult Clinical Study**:
  - **Sentence**: ""A double-blind, placebo-controlled, fixed-dose, parallel group, two-week study was",Most,Yes,1,1,